VANCOUVER, Sept. 23 /CNW/ - Angiotech Pharmaceuticals, Inc. ("Angiotech")
(NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device
company, today announced that it has terminated its previously announced
tender offer (the "Tender Offer") for its outstanding Senior Floating Rate
Notes Due 2013 (CUSIP No. 034918AF9) (the "First Priority Notes"), and its
outstanding 7.75% Senior Subordinated Notes Due 2014 (CUSIP No. 034918AC6)
(the "Second Priority Notes" and collectively with the First Priority Notes,
the "Notes"). None of the Notes were purchased in the Tender Offer and all
Notes previously tendered and not withdrawn will be promptly returned to their
respective holders.
